Role of protein kinases in the development of Tamoxifen and Palbociclib resistance in breast cancer

NOVARO VIRGINIA; RIGGIO MARINA; RODRIGUEZ MARIA JIMENA; ENRICO DIEGO; PERRONE MARIA CECILIA; ALCOBER LUCIA; POLO MARIA LAURA

Ciudad de Buenos Aires

Congreso; Reunión Conjunta de Sociendades de Biociencias; 2017

Sociedad Argentina de Investigación Clínica

It is estimated that approximately 70% of breast tumors express hormone receptors for estrogen (ER) and progesterone (PR). Although ER antagonist tamoxifen has been successful for ER+ breast cancer treatment, a significant amount of these tumors eventually develop resistance. In order to study this phenomenon, we generated a tamoxifen-resistant cell line derived from the human breast cancer cell line T47D (T47D-TR), by long-term cell exposure to progressively increasing concentrations of tamoxifen. This resistant cell line showed an increase in basal activation of ER despite reduction in its expression levels (p